arginase inhibitor in the pharmacological correction of endothelial dysfunction

arginase inhibitor in the pharmacological correction of endothelial dysfunction

;Mihail V. Pokrovskiy;Mihail V. Korokin;Svetlana A. Tsepeleva;Tatyana G. Pokrovskaya;Vladimir V. Gureev;Elena A. Konovalova;Oleg S. Gudyrev;Vladimir I. Kochkarov;Liliya V. Korokina;Eleonora N. Dudina;Anna V. Babko;Elena G. Terehova
molecular biology and evolution 2011 Vol. 2011 pp. -
103
pokrovskiy2011internationalarginase

Abstract

This paper is about a way of correction of endothelial dysfunction with the inhibitor of arginase: L-norvaline. There is an imbalance between vasoconstriction and vasodilatation factors of endothelium on the basis of endothelial dysfunction. Among vasodilatation agents, nitrogen oxide plays the basic role. Amino acid L-arginine serves as a source of molecules of nitrogen oxide in an organism. Because of the high activity of arginase enzyme which catalyzes the hydrolysis of L-arginine into ornithine and urea, the bioavailability of nitrogen oxide decreases. The inhibitors of arginase suppress the activity of the given enzyme, raising and production of nitrogen oxide, preventing the development of endothelial dysfunction.

Citation

ID: 252597
Ref Key: pokrovskiy2011internationalarginase
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
252597
Unique Identifier:
10.4061/2011/515047
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet